ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1743

Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies

Lyndsey Cole1, Sucai Liu2, Brendan Allen2, Marie Feser3, Kristen Demoruelle3, kevin Deane3, Michael Holer3 and kristine Kuhn2, 1University of Colorado School of Medicine, Centennial, CO, 2University of Colorado School of Medicine, Aurora, CO, 3University of Colorado Anschutz Medical Campus, Aurora, CO

Meeting: ACR Convergence 2023

Keywords: Anti-ACPA, microbiome, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Our prior investigation identified a specific strain of Subdoligranulum didolesgii, S. dido7, to which dual IgA/IgG family plasmablast-derived monoclonal autoantibodies from individuals at-risk for RA show cross-reactivity with RA-relevant autoantigens. S. dido7 stimulated CD4+ T cell activation in individuals with RA. Also, it led to inflammatory arthritis (IA) in mono-colonized germ-free mice and Th17 cell expansion, RA-relevant IgG autoantibody production and colon-isolated lymphoid follicle abundance [1]. In this study, we sought to assess the prevalence and compare the fecal concentration of S. dido7 among healthy controls vs. individuals at-risk and with early RA and its association with CCP3 antibodies and biomarkers of intestinal permeability, zonulin and soluble CD14.

Methods: Stool and sera were prospectively collected from 3 groups: 1) ‘At-Risk’ individuals, defined as those with positive CCP3 with no history of nor current IA (n=54), 2) individuals with CCP3(+) RA based on 2010 ACR/EULAR criteria within 12 months of diagnosis (n=5) and 3) controls without IA or RF/CCP3 positivity (n=32). Exclusion criteria included antibiotics in the 3 months prior to sample collection. Fecal DNA was extracted using a commercial kit (Qiagen). Quantitative PCR was used to create a standard curve using known concentrations of S. dido7 to allow for calculation of strain-specific fecal levels in individual samples. Serum CCP3 ELISA (Werfen) was used to measure CCP IgG. Serum ELISAs (Cusabio) were used to quantitate serum zonulin and soluble CD14.

Results: Demographics are summarized in Table 1. There were no significant differences across the groups apart from age. Fecal concentration of S. dido7 was 2.5-fold higher in At-Risk individuals and 3.1-fold higher in early RA compared to controls (p=0.02; Figure 1). Higher serum CCP3 levels significantly correlated with higher fecal S. dido 7 concentration (p=0.005; Table 2). Serum CD14 but not zonulin was significantly lower in At-Risk individuals and early RA (p=0.008; Table 1). Higher zonulin significantly correlated with lower fecal S. dido7 concentration (p=0.002; Table 2). There was no significant correlation between fecal S. dido7 and serum soluble CD14 or age (Table 2).

Conclusion: These data, along with prior data demonstrating arthritogenic potential of this bacterial strain, suggestS. dido7 may play an important mechanistic role in a subset of individuals during development of CCP autoantibodies and subsequent RA. Our data do not agree with others’ findings of impaired intestinal permeability that we hypothesized as a potential mechanism by whichS. dido7 may trigger autoimmunity. Future study is needed to address limitations, including validation of intestinal permeability studies and improvement in age- and sex-matching, as well as to evaluateS. dido7 in seronegative RA and its associations with clinical and biomarker features before and after arthritis development.

[1] Chriswell ME, Lefferts AR, Clay MR, et al. Clonal IgA and IgG autoantibodies from individuals at risk for rheumatoid arthritis identify an arthritogenic strain of Subdoligranulum. Sci Transl Med. 2022 Oct 26;14(668):eabn5166. doi: 10.1126/scitranslmed.abn5166. Epub 2022 Oct 26.

Supporting image 1

Supporting image 2

Figure 1: Fecal concentration of S. dido 7 in ng/L significantly differed across the three groups by Kruskal-Wallis test (p=0.02). After adjustment for multiple comparisons, the At-Risk group had a significantly higher fecal concentration of S. dido 7 compared to the control group by Mann-Whitney test (p=0.024).

Supporting image 3


Disclosures: L. Cole: Appleton Medical Services, 12, Spouse is an employee for Appleton Medical (sales representative); S. Liu: None; B. Allen: None; M. Feser: None; K. Demoruelle: Boehringer-Ingelheim, 5, Gilead, 5, Pfizer, 5; k. Deane: Bristol-Myers Squibb(BMS), 1, Gilead, 5, Janssen, 5, Werfen, 1, 12, Biomarker kits; M. Holer: None; k. Kuhn: pfizer, 5, ucb, 2.

To cite this abstract in AMA style:

Cole L, Liu S, Allen B, Feser M, Demoruelle K, Deane k, Holer M, Kuhn k. Individuals At-risk for and with Rheumatoid Arthritis Have Elevated Fecal Concentrations of Arthritogenic Subdoligranulum didolesgii Correlating with CCP3 Antibodies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/individuals-at-risk-for-and-with-rheumatoid-arthritis-have-elevated-fecal-concentrations-of-arthritogenic-subdoligranulum-didolesgii-correlating-with-ccp3-antibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/individuals-at-risk-for-and-with-rheumatoid-arthritis-have-elevated-fecal-concentrations-of-arthritogenic-subdoligranulum-didolesgii-correlating-with-ccp3-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology